Atlas Trials

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Clinical trial NCT03126916 · RECRUITING

Trial details

NCT number
NCT03126916
Sponsor
Children's Oncology Group
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma
Start date
2018-05-14
Primary completion
2030-09-30
Enrollment
750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.